<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826497</url>
  </required_header>
  <id_info>
    <org_study_id>2021KC20122</org_study_id>
    <nct_id>NCT04826497</nct_id>
  </id_info>
  <brief_title>Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction</brief_title>
  <official_title>Effects of Nicorandil on Cardiac Sympathetic Nerve Activity and Distribution in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuzhou Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators evaluate the effects of intracoronary and intravenous administration of&#xD;
      nicorandil on cardiac sympathetic nerve activity and distribution in patients with acute&#xD;
      myocardial infarction undergoing primary percutaneous coronary intervention&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reperfusion injury might occur in patients with acute ST segment elevation myocardial&#xD;
      infarction undergoing the primary percutaneous coronary intervention(P-PCI),characterized by&#xD;
      myocardial stunning, reperfusion-induced arrhythmia, microvascular dysfunction and injury of&#xD;
      cardiac sympathetic nerve, etc.&#xD;
&#xD;
      Nicorandil is an antianginal agent with a dual mechanism of action: nitrate and K+ATP channel&#xD;
      opener. The nitrate action causes vasodilation of systemic veins and epicardial coronary&#xD;
      arteries, while the adenosine triphosphate (ATP)-sensitive potassium channel opener action&#xD;
      causes vasodilation of peripheral and coronary resistance arterioles. Nicorandil not only&#xD;
      decreases preload and afterload but also increases coronary blood flow.&#xD;
&#xD;
      The study will compare the effectiveness between nicorandil and placebo of preventing the&#xD;
      reperfusion injury especially injury of cardiac sympathetic nerve in patients with acute ST&#xD;
      segment elevation myocardial infarction undergoing the P-PCI.It is intended that before&#xD;
      reperfusion injury ,nicorandil which was early used by intracoronary injection could prevent&#xD;
      and release the microcirculatory spasm, release the coronary microvascular endothelial&#xD;
      swelling,decrease embolism of atherosclerotic debris and thrombus formation,moreover,it could&#xD;
      reduces the release of norepinephrine from sympathetic endings of the heart directly.So,it&#xD;
      could decrease the phenomenon of no-reflow/slow reflow,reperfusion-induced arrhythmia and&#xD;
      injury of cardiac sympathetic nerve.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the delayed heart/mediastinum count (H/M) ratio</measure>
    <time_frame>10 days after primary PCI</time_frame>
    <description>The delayed heart/mediastinum count (H/M) ratio was determined from 123I-meta-iodobenzylguanidine (MIBG) images</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The total defect score (TDS)</measure>
    <time_frame>10 days after primary PCI</time_frame>
    <description>The total defect score was determined from 123I-meta-iodobenzylguanidine (MIBG) images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of slow re-flow/no-reflow phenomenon</measure>
    <time_frame>5 minutes after primary PCI</time_frame>
    <description>TIMI myocardial perfusion grade (TMPG) of the final coronary flow in the culprit artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate fo complete ST-segment resolution</measure>
    <time_frame>2 hours after primary PCI</time_frame>
    <description>ST-segment resolution &gt;50 percent in ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of unplanned hospitalization for heart failure</measure>
    <time_frame>6 months after primary PCI</time_frame>
    <description>Rate of unplanned hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The washout rate (WR)</measure>
    <time_frame>10 days after primary PCI</time_frame>
    <description>The washout rate (WR) were determined from 123I-meta-iodobenzylguanidine (MIBG) images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total defect score (TDS)</measure>
    <time_frame>7 days after primary PCI</time_frame>
    <description>The total defect score was determined from 99mTc-pyrophosphate scintigraphy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Nicorandil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received intracoronary and intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo （normal saline）</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who received intracoronary and intravenous placebo before and after reperfusion with primary percutaneous coronary intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicorandil</intervention_name>
    <description>All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg nicorandil was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention</description>
    <arm_group_label>Nicorandil</arm_group_label>
    <other_name>Experiment Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo（normal saline）</intervention_name>
    <description>All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention</description>
    <arm_group_label>Placebo （normal saline）</arm_group_label>
    <other_name>Control Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. acute ST-segment elevation myocardial infarction within 12 hours of symptom onset;&#xD;
&#xD;
          2. Age20-80,All genders&#xD;
&#xD;
          3. anterior myocardial infarction&#xD;
&#xD;
          4. The first myocardial infarction&#xD;
&#xD;
          5. The infarct-related artery(IRA) is totally occlusive&#xD;
&#xD;
          6. Blood pressure is higher than 90/60 millimeters of mercury（mmHg）&#xD;
&#xD;
          7. The time from myocardial infarction onset to reach the hospital is less than 12 hs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. kidney dysfunction (creatinine &gt;2 mg/dl),&#xD;
&#xD;
          2. History of previous liver disease,&#xD;
&#xD;
          3. Cardiogenic shock,&#xD;
&#xD;
          4. History of myocardial infarction (MI)&#xD;
&#xD;
          5. History of coronary artery bypass grafting&#xD;
&#xD;
          6. History of allergic response to drugs&#xD;
&#xD;
          7. Severe hypovolemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Institute of Cardiovascular Disease Xuzhou Central Hospital</last_name>
    <role>Study Director</role>
    <affiliation>Southeast University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>chunguang Feng, PhD</last_name>
    <phone>+8618936376559</phone>
    <email>fcg999@163.com</email>
  </overall_contact>
  <results_reference>
    <citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.</citation>
    <PMID>28886621</PMID>
  </results_reference>
  <results_reference>
    <citation>Piper HM, Meuter K, Schäfer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg. 2003 Feb;75(2):S644-8. Review.</citation>
    <PMID>12607706</PMID>
  </results_reference>
  <results_reference>
    <citation>Ji Z, Zhang R, Lu W, Ma G, Qu Y. The effect of nicorandil in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Ir J Med Sci. 2020 Feb;189(1):119-131. doi: 10.1007/s11845-019-02034-3. Epub 2019 May 30.</citation>
    <PMID>31147987</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu L, Wang L, Li K, Zhang Z, Sun H, Yang X. Nicorandil prior to primary percutaneous coronary intervention improves clinical outcomes in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2019 Apr 29;13:1389-1400. doi: 10.2147/DDDT.S195918. eCollection 2019. Review.</citation>
    <PMID>31118574</PMID>
  </results_reference>
  <results_reference>
    <citation>Fukui Y, Nozawa T, Ihori H, Sobajima M, Nakadate T, Matsuki A, Nonomura M, Fujii N, Inoue H, Kinugawa K. Nicorandil Attenuates Ischemia-Reperfusion Injury Via Inhibition of Norepinephrine Release From Cardiac Sympathetic Nerve Terminals. Int Heart J. 2017 Oct 21;58(5):787-793. doi: 10.1536/ihj.16-391. Epub 2017 Sep 30.</citation>
    <PMID>28966311</PMID>
  </results_reference>
  <results_reference>
    <citation>Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction. Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):322-8. Epub 2004 Oct 2.</citation>
    <PMID>15791442</PMID>
  </results_reference>
  <results_reference>
    <citation>Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll Cardiol. 2018 Mar 6;71(9):1021-1034. doi: 10.1016/j.jacc.2017.12.048. Review.</citation>
    <PMID>29495982</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nicorandil</keyword>
  <keyword>primary percutaneous coronary intervention</keyword>
  <keyword>acute ST segment elevation myocardial infarction</keyword>
  <keyword>cardiac sympathetic nerve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicorandil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

